Global Sexually Transmitted Diseases (STD) Treatment Market 2019-2023
SKU ID : TNV-14098760 | Publishing Date : 29-Mar-2019 | No. of pages : 120
Detailed TOC of Global Sexually Transmitted Diseases (STD) Treatment Market 2019-2023
PART 01: EXECUTIVE SUMMARYPART 02: SCOPE OF THE REPORT
• 2.1 Preface
• 2.2 Preface
• 2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 04: MARKET SIZING
• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 06: MARKET SEGMENTATION BY TYPE
• Market segmentation by type
• Comparison by type
• Viral infections - Market size and forecast 2018-2023
• Bacterial infections - Market size and forecast 2018-2023
• Other infections - Market size and forecast 2018-2023
• Market opportunity by type
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
• Geographic segmentation
• Geographic comparison
• North America - Market size and forecast 2018-2023
• Europe - Market size and forecast 2018-2023
• Asia - Market size and forecast 2018-2023
• ROW - Market size and forecast 2018-2023
• Key leading countries
• Market opportunity
PART 09: DECISION FRAMEWORK
PART 10: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 11: MARKET TRENDS
• Market trends
PART 12: VENDOR LANDSCAPE
• Overview
• Landscape disruption
PART 13: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• Bristol-Myers Squibb Company
• Gilead Sciences, Inc.
• GlaxoSmithKline plc
• Johnson & Johnson Services, Inc.
• Merck & Co., Inc.
PART 14: APPENDIX
• Research methodology
• List of abbreviations
PART 15: EXPLORE TECHNAVIO
Exhibit 01: Global pharmaceuticals market
Exhibit 02: Segments of global pharmaceuticals market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2018
Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 09: Five forces analysis 2018
Exhibit 10: Five forces analysis 2023
Exhibit 11: Bargaining power of buyers
Exhibit 12: Bargaining power of suppliers
Exhibit 13: Threat of new entrants
Exhibit 14: Threat of substitutes
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition - Five forces 2018
Exhibit 17: Type - Market share 2018-2023 (%)
Exhibit 18: Comparison by type
Exhibit 19: Viral infections - Market size and forecast 2018-2023 ($ millions)
Exhibit 20: Viral infections - Year-over-year growth 2019-2023 (%)
Exhibit 21: Bacterial infections - Market size and forecast 2018-2023 ($ millions)
Exhibit 22: Bacterial infections - Year-over-year growth 2019-2023 (%)
Exhibit 23: Other infections - Market size and forecast 2018-2023 ($ millions)
Exhibit 24: Other infections - Year-over-year growth 2019-2023 (%)
Exhibit 25: Market opportunity by type
Exhibit 26: Customer landscape
Exhibit 27: Market share by geography 2018-2023 (%)
Exhibit 28: Geographic comparison
Exhibit 29: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 30: North America - Year-over-year growth 2019-2023 (%)
Exhibit 31: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 32: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 33: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 34: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 35: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 36: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 37: Key leading countries
Exhibit 38: Market opportunity
Exhibit 39: Pipeline drugs for STDs
Exhibit 40: Impact of drivers and challenges
Exhibit 41: Some of the HIV vaccines under clinical trials
Exhibit 42: Vendor landscape
Exhibit 43: Landscape disruption
Exhibit 44: Vendors covered
Exhibit 45: Vendor classification
Exhibit 46: Market positioning of vendors
Exhibit 47: Bristol-Myers Squibb Company - Vendor overview
Exhibit 48: Bristol-Myers Squibb Company - Business segments
Exhibit 49: Bristol-Myers Squibb Company - Organizational developments
Exhibit 50: Bristol-Myers Squibb Company - Geographic focus
Exhibit 51: Bristol-Myers Squibb Company - Key offerings
Exhibit 52: Gilead Sciences, Inc. - Vendor overview
Exhibit 53: Gilead Sciences, Inc. - Business segments
Exhibit 54: Gilead Sciences, Inc. - Organizational developments
Exhibit 55: Gilead Sciences, Inc. - Geographic focus
Exhibit 56: Gilead Sciences, Inc. - Key offerings
Exhibit 57: GlaxoSmithKline plc - Vendor overview
Exhibit 58: GlaxoSmithKline plc - Business segments
Exhibit 59: GlaxoSmithKline plc - Organizational developments
Exhibit 60: GlaxoSmithKline plc - Geographic focus
Exhibit 61: GlaxoSmithKline plc - Segment focus
Exhibit 62: GlaxoSmithKline plc - Key offerings
Exhibit 63: Johnson & Johnson Services, Inc. - Vendor overview
Exhibit 64: Johnson & Johnson Services, Inc. - Business segments
Exhibit 65: Johnson & Johnson Services, Inc. - Organizational developments
Exhibit 66: Johnson & Johnson Services, Inc. - Geographic focus
Exhibit 67: Johnson & Johnson Services, Inc. - Segment focus
Exhibit 68: Johnson & Johnson Services, Inc. - Key offerings
Exhibit 69: Merck & Co., Inc. - Vendor overview
Exhibit 70: Merck & Co., Inc. - Business segments
Exhibit 71: Merck & Co., Inc. - Organizational developments
Exhibit 72: Merck & Co., Inc. - Geographic focus
Exhibit 73: Merck & Co., Inc. - Segment focus
Exhibit 74: Merck & Co., Inc. - Key offerings
Exhibit 75: Validation techniques employed for market sizing
Keyplayers in Global Sexually Transmitted Diseases (STD) Treatment Market 2019-2023
Bristol-Myers Squibb CompanyGilead Sciences, Inc.
GlaxoSmithKline plc
Johnson & Johnson Services, Inc.
Merck & Co., Inc.